Author:
Khalil Ashraf,Jameson Mark J.
Publisher
Springer Science and Business Media LLC
Subject
Cancer Research,Endocrine and Autonomic Systems,Endocrinology,Oncology,Endocrinology, Diabetes and Metabolism
Reference47 articles.
1. Bower R, Green VL, Kuvshinova E, Kuvshinov D, Karsai L, Crank ST, Stafford ND, Greenman J (2017) Maintenance of head and neck tumor on-chip: gateway to personalized treatment? Future Sci OA 3(2):FSO174
2. Ahn PH, Machtay M, Anne PR, Cognetti D, Keane WM, Wuthrick E, Dicker AP, Axelrod RS (2016) Phase I trial using induction cisplatin, docetaxel, 5-FU and erlotinib followed by cisplatin, bevacizumab and erlotinib with concurrent radiotherapy for advanced head and neck cancer. Am J Clin Oncol
3. Yang J, Ju Z, Dong S (2016) Cisplatin and paclitaxel co-delivered by folate-decorated lipid carriers for the treatment of head and neck cancer. Drug Deliv 24(1):792–799
4. Wang HM, Lin CY, Hsieh CH, Hsu CL, Fan KH, Chang JT, Huang SF, Kang CJ, Liao CT, Ng SH, Yen TC (2017) Induction chemotherapy with dose-modified docetaxel, cisplatin, and 5-fluorouracil in Asian patients with borderline resectable or unresectable head and neck cancer. J Formos Med Assoc 116(3):185–192
5. Denduluri SK, Idowu O, Wang Z, Liao Z, Yan Z, Mohammed MK, Ye J, Wei Q, Wang J, Zhao L, Luu HH (2015) Insulin-like growth factor (IGF) signaling in tumorigenesis and the development of cancer drug resistance. Genes Dis 2(1):13–25
Cited by
12 articles.
订阅此论文施引文献
订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献